Abstract
Objective: the aim of this article was to carried out an exploration of the predictive value of serum high-sensitivity C-reactive protein (hs-CRP) plus high levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) for the onset of ischemic stroke (IS).
Material and Method: 526 IS patients were selected as the experimental group (EG). During the same period, 463 healthy individuals served as the control group (CG). The levels of Lp-PLA2, myeloperoxidase (MPO), total cholesterol (CHO), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), hs-CRP, and serum ferritin (SF) in the serum of subjects were compared. The predictive efficacy of combination of two for the onset of IS was assessed.
Result: the levels of Lp-PLA2, MPO, CHO, LDL, TG, hs-CRP, and SF in patients with IS were all markedly higher as against the CG (P<0.05). Multivariate Logistic regression analysis (MLRA) suggested that both hs-CRP and Lp-PLA2 were independently associated with the risk of IS (OR=1.334, 95%CI=1.713~1.954; 1.251, 1.011~1.921). The ROC curve analysis revealed that the predictive efficacy for IS of hs-CRP in combination with Lp-PLA2 (area under the ROC curve (AUC)=0.786) was markedly better as against hs-CRP alone (0.713) or Lp-PLA2 alone (0.698) (P<0.05).
Conclusion: serum hs-CRP in conjunction with elevated Lp-PLA2 levels demonstrated obvious predictive value for IS, aiding in the early identification of high-risk groups.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.